Figurę 4: VSV therapy in the B16 tu mor model. C57B1/6 mice (n=l 1-26) were injected subcutaneously with B16 cells and infected locally at the tumor site with 5.0 x 108 PFU of WT or mutant VSV on day 7, 9 and 11. Survival (tumors < 1.7 cm in any diameter) is shown (a) as well as the percentage of mice with definite tumor areas at indicated time points (b). Data show three combined independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.